Month: September 2026

Operational Highlights August

• Occupancy reached 85%, up 2% points from last August. 
• Average Cabin Revenue (ACR) increased by 11% compared to August 2025.
• Total ticket revenue increased by 14% compared to August last year.
• Operational onboard revenue grew by 14% compared to August last year.

Booking Position 2026

• Solid position for 2026, with 75% of capacity booked – compared to 68% at the same time last year, around 7 percentage points (or 11% higher) ahead.
• We target +10% ACR growth across cabin categories for 2026, supporting continued revenue growth and EBITDA margin expansion.

Booking Position 2027

• 30% of 2027 capacity is booked, one percentage points behind the same time last year mainly due to lower group allotments (individual bookings are three percentage points higher than same time last year).

*The KPIs provided are sourced from the Company’s (unaudited) booking system. Consequently, there may be variations or minor discrepancies in absolute figures and periodization compared to the reported financial statements. Revenue in currency (for ACR) is based on the booking system currency rate.

Contacts:
Chief Executive Officer: Bent Martini, +47 905 99 650
Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114

 

Schindellegi, Switzerland – 14 September 2026

Trifork Group AG
Company announcement no. 54/2026

Weekly report on share buyback

On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026.

Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million).

Under the program, the following transactions have been made:

Date	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Total beginning	461,725	99.08	45,747,918
7 September 2026	6,000	108.75	652,500
8 September 2026	6,500	107.58	699,270
9 September 2026	6,500	106.47	692,055
10 September 2026	6,300	106.51	671,013
11 September 2026	6,000	105.40	632,400
Accumulated	493,025	99.58	49,095,156

A detailed overview of the daily transactions can be found here: https://investor.trifork.com/trifork-shares/.

With the transactions stated above, the total accumulated amount of treasury shares acquired under the current share buyback program corresponds to 2.5% of the share capital of Trifork Group AG. Trifork Group owns 760,308 treasury shares in total, corresponding to 3.9% of the share capital.

Investor & Media contact
Frederik Svanholm, Group Investment Director, frsv@trifork.com, +41 79 357 7317

About Trifork Group
Trifork (Nasdaq Copenhagen: TRIFOR) is a global technology company specializing in designing, building, and operating advanced software for enterprise and public sector customers. With 1,118 FTEs across 16 countries, Trifork serves as an end-to-end technology partner to organizations in complex and regulated industries, including public administration, healthcare, financial services, energy, and aviation.
Learn more at trifork.com.

Attachment

• CA_54_2026_Buyback

Vilnius, Lithuania, Sept. 14, 2026 (GLOBE NEWSWIRE) —

SUTNTIB AB Tewox, legal entity code 305733600, with its registered office at Jogailos g. 4, Vilnius, Republic of Lithuania (the Issuer).

The Issuer announces that, pursuant to the Issuer’s Base Prospectus approved by the Bank of Lithuania on 13 July 2026 (the Prospectus) and the approved Final Terms of the second tranche of the Issuer’s bonds (ISIN LT0000138281) (the Final Terms), the offering of the bonds under the Final Terms in the amount of up to EUR 19 million (subject to increase as provided for in the Final Terms) will be carried out in the Republic of Lithuania, the Republic of Latvia, and the Republic of Estonia from 14 September 2026 under the following main terms (other terms applicable to the offering are detailed in the Final Terms and the Prospectus):

• Nominal Value of a Bond – EUR 1,000;
• Issue Price of a Bond – EUR 1,008.99274 (with accrued interest);
• Final Maturity Date – 21 February 2029;
• Interest Rate – 8.00% (fixed) annually;
• Yield – 8.00% annually;
• Subscription channels – subscription by way of Nasdaq Auction through the Exchange Members (list https://nasdaqbaltic.com/statistics/lt/members);
• Subscription Period – 14 September 2026 – 29 September 2026;
• Exchange – the investors have an opportunity to exchange their bonds (ISIN LT0000409567) for the bonds of the new bond issue (ISIN LT0000138281) on a 1-to-1 basis through Nasdaq CSD;
• Issue Date – 2 October 2026.

Before deciding to invest in the Bonds, each prospective investor shall read the Prospectus and Final Terms (as may be updated) with the attached relevant language summary. All aforementioned documents are attached herein and are published on the Issuer’s website at www.lordslb.lt/tewox_bonds/.

Contact person for further information:

Paulius Nevinskas
Manager of the Investment Company
paulius.nevinskas@lordslb.lt
https://lordslb.lt/tewox_bonds/

Attachments

• SUTNTIB AB TEWOX 2nd tranche final terms and summary
• 2026-09 Tewox bonds 2nd Tranche
• Tewox Base Prospectus_13.07.2026_EXE
• SUTNTIB AB TEWOX 2nd tranche summary_LV
• SUTNTIB AB TEWOX 2nd tranche summary_EE

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	11th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	36,580	302.5	280.75
Ordinary shares	Sales	24,080	310.8	278.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	14th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Gooch & Housego plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor and Broker to Gooch & Housego plc
(d)        Date dealing undertaken:	11th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Sales	8,282	1207.5	1205

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	14th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Gamma Communications Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Gamma Communications Plc
(d)        Date dealing undertaken:	11th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	295,029	1141.5	1110
Ordinary shares	Sales	295,029	1141.5	1110

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	14th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	11th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	218,454	280.75	280.5
Ordinary shares	Sales	1,144,179	281	280.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	14th September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquired under the First Tranche will be used to meet obligations arising from employee share-based incentive programs.

The maximum number of shares acquired by the company per daily market session will be equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days. The share buyback program will be conducted in accordance with Article 5 of Regulation (EU) No. 596/2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (the Safe Harbour Rules).

Attachment

• 2026_17_Initiation_of_share_buyback

Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, and by updating its culture with ‘The Novo Way’ that will enable the company to move ahead with greater focus, speed and impact. Together, the rebrand and ‘The Novo Way’ are part of how the company will deliver on its business objectives and its ambition to bring better health to many more people.

“People have always been at the centre of Novo’s science. We have transformed major areas of healthcare, such as obesity and diabetes, by bringing innovation to conditions that affect millions of lives. But the unmet need remains vast, and at the same time, people’s expectations of healthcare are changing,” said Mike Doustdar, president and CEO, Novo. “Healthcare must become more responsive, relevant and easier to fit into everyday life. Our brand and culture are strategically important and will enhance how we operate and compete, but the reason we exist will not change. We remain true to our purpose of changing people’s lives and are ambitious about our future to help them have lasting health, starting right now.”

The rebrand
‘Lasting Health Starts Now’ is at the centre of the rebrand and is based on the idea that lasting health begins today, not someday, through progress people can see and feel day by day. The rebrand will give the company a distinctive, recognisable and consistent way to connect with people, partners and other stakeholders around the world. ‘Novo’ will be used as the name of the company day-to-day, while Novo Nordisk A/S remains the legal global company name. The updated visual identity includes the Apis bull logo rooted in Novo’s heritage, while giving the brand a contemporary and future-fit expression.

The rebrand is designed to be more memorable and relevant to the way people engage with their health today. It also reflects the company’s ambition to bring breakthrough science closer to people’s daily lives and to strengthen recognition and trust as Novo reaches more people in more ways.

Corporate culture
‘The Novo Way’, introduced today, is a new set of principles that will underpin the company’s culture, building on the strengths that have defined Novo for more than a century – breakthrough science, deep expertise, care for people, and an unwavering commitment to patient safety – while setting out the behaviours and ways of working needed to innovate and lead in a faster, more competitive and increasingly consumer-driven market.

‘The Novo Way’ is built around four principles:

1. Customer Obsession – We innovate with consumers and patients at the centre of everything we do
2. Competitiveness – We raise our performance to create greater value for all our stakeholders
3. Clarity – We create focus and speed through clear priorities, simple ways of working and decisive action
4. Care & Integrity – We care for our people, show respect, and never compromise on patient safety and ethics

“Brand and culture work together: culture shapes how we reach our strategy and how we work, while brand shapes the value that people attach to our products and services, and how our company is perceived around the world,” said Tania Sabroe, executive vice president, People, Organisation & Corporate Affairs, Novo. “Our updated culture will enable us to move with focus and speed, and our rebrand ensures we show up with relevance and distinctiveness across medicines, partnerships, marketing and stakeholder engagement. Together, these will sharpen our competitive edge and strengthen our role as a trusted partner in healthcare.”

At its Capital Markets Day on 21 September in London, Novo will provide a detailed overview of the updated corporate strategy. Details can be found on the Investor Relations page of novonordisk.com.

To see more of the new Novo brand elements and the Novo Way, go to novonordisk.com.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Attachment

• PR260914-New-Brand